コンテンツへスキップ
Merck
  • Anti-aggregation effect on platelets of Indiplon a hypnotic sedative non-benzodiazepine drug.

Anti-aggregation effect on platelets of Indiplon a hypnotic sedative non-benzodiazepine drug.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2018-12-30)
C F Burgos, C Sanchéz, C Sepúlveda, E Fuentes, I Palomo, M Alarcón
要旨

Cardiovascular diseases are one of the main public health problems, and many of them, their pathophysiology involves alterations in platelet activity. Platelet activation is an essential event that is regulated by the intracellular concentrations of Ca2+ and cAMP. Interestingly, it has been shown that the activation of adenosine A2A receptors increases cAMP levels and produces the inhibition of platelet aggregation, which appears as a potential target for regulation of platelet activity. Therefore, we tried to activate A2A receptors using Indiplon, a drug developed for the treatment of insomnia, and analyze its effect on platelet activity in vitro. Our results indicate that Indiplon is able to interact in silico with the adenosine A2A receptor (ΔGbind of -73.321 kcal/mol, similar to that obtained with adenosine), which is involved in the regulation of platelet cAMP levels. In functional studies using PRP, a reduction in platelet aggregation induced by ADP was observed in the presence of Indiplon at 500 μM with a percentage of inhibition 70%, where the use of specific inhibitors (ZM241385 and MSX-2) of the A2A receptor also blocked these effects reducing the percentage of inhibition to 41% and 34.1%, respectively. Also, the use of Indiplon produced a decrease in the expression in the membrane of P-selectin. Thus, Indiplon acts as an A2A receptor agonist and whose activation results in inhibition of platelet aggregation and activation, showing a possible cardiovascular protective role.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
Indiplon, ≥98% (HPLC)